Tornado diagrams of the sensitivity analyses.

<p>Diagram A) describes scenario 1a and diagram B) scenario describes scenario 1b. Both diagrams show the change in ICER when reducing or increasing each parameter with 25%.</p

Schematic description of the Markov model.

<p>Annually, women move between health stages according to defined transition rates given in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0070319#pone-0070319-t001" target="_blank">Table 1</a>. The natural history of HCV infection (hepatitis C virus) is modelled through the stages of chronic infection, cirrhosis, decompensated cirrhosis, hepatocellular carcinoma (HCC), liver transplantation, and the years after transplantation. The dotted arrows indicate competing mortality. In <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0070319#pone-0070319-g001" target="_blank">Figure 1A</a> the model is presented for the women who are not routinely screened for HCV during their pregnancy and are diagnosed in a later stage of infection, in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0070319#pone-0070319-g001" target="_blank">Figure 1b</a> the model is presented for women who are routinely screened during their pregnancy.</p

Overview of annual transition probabilities and cost variables used in the Markov model.

<p>HCV: hepatitis C virus.</p><p>HCC: hepatocellular carcinoma.</p>#<p>In the prevalence a clearance rate of 42% <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0070319#pone.0070319-Rozenbaum1" target="_blank">[14]</a> was included. The prevalence used in the model for all pregnant women is 0.2% (9/4563; 95% CI: 0.10–0.37) and for first generation non-Western women 0.43% (7/1612; 95% CI 0.21–0.89).</p>$<p>Transition rate is age-dependent.</p>*<p>same distribution was used for first-generation non-Western women.</p>**<p>new protease inhibitors are added to the standard of care regimen (peginterferon alfa and ribavirine).</p

Best-case scenarios for screening all pregnant women (scenario 1a) and first-generation non-Western women (scenario 1b).

<p>With parameter optimization ±25% and incremental cost-effectiveness ratio calculated with reference to the “no routine screening” strategy.</p><p>LYG:life years gained.</p><p>ICER: incremental cost-effectiveness ratio.</p

Cost-effectiveness outcomes for all pregnant women and first-generation non-Western women (scenarios 1a and 1b), based on probabilistic uncertainty analysis (10000 simulations).

<p>The incremental cost-effectiveness ratio (ICER) is calculated with reference to the “no routine screening” strategy.</p><p>LYG:life years gained.</p><p>ICER: incremental cost-effectiveness ratio.</p